- Home
- TLPH vs ABVC Comparison
TLPH vs ABVC Comparison
Compare TLPH & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- ABVC
- Stock Information
- Founded
- TLPH 2005
- ABVC 2015
- Country
- TLPH United States
- ABVC United States
- Employees
- TLPH N/A
- ABVC N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- ABVC Health Care
- Exchange
- TLPH Nasdaq
- ABVC Nasdaq
- Market Cap
- TLPH 12.7M
- ABVC 12.8M
- IPO Year
- TLPH 2011
- ABVC N/A
- Fundamental
- Price
- TLPH $0.63
- ABVC $0.49
- Analyst Decision
- TLPH Strong Buy
- ABVC
- Analyst Count
- TLPH 2
- ABVC 0
- Target Price
- TLPH $4.50
- ABVC N/A
- AVG Volume (30 Days)
- TLPH 101.8K
- ABVC 107.7K
- Earning Date
- TLPH 03-05-2025
- ABVC 03-12-2025
- Dividend Yield
- TLPH N/A
- ABVC N/A
- EPS Growth
- TLPH N/A
- ABVC N/A
- EPS
- TLPH N/A
- ABVC N/A
- Revenue
- TLPH $281,000.00
- ABVC $509,788.00
- Revenue This Year
- TLPH N/A
- ABVC N/A
- Revenue Next Year
- TLPH N/A
- ABVC N/A
- P/E Ratio
- TLPH N/A
- ABVC N/A
- Revenue Growth
- TLPH N/A
- ABVC N/A
- 52 Week Low
- TLPH $0.50
- ABVC $0.41
- 52 Week High
- TLPH $1.61
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- TLPH 46.28
- ABVC 40.02
- Support Level
- TLPH $0.54
- ABVC $0.46
- Resistance Level
- TLPH $0.73
- ABVC $0.55
- Average True Range (ATR)
- TLPH 0.07
- ABVC 0.03
- MACD
- TLPH -0.00
- ABVC -0.00
- Stochastic Oscillator
- TLPH 31.46
- ABVC 29.66
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.